Methotrexate Market Share

North America Market Forecast

In methotrexate market, North America region is likely to hold more than 33.7% revenue share by 2037. The presence of advanced healthcare facilities, the existence of key pharma companies, and the rising prevalence of autoimmune diseases are augmenting the demand for methotrexate solutions. The supportive reimbursement policies are further contributing to the overall market growth.

In, the U.S., the increasing cases of cancer coupled with the rise in the stressful lifestyles of individuals is pushing the demand for effective treatment formulations such as methotrexate. The National Cancer Institute reveals that in 2024, an estimated 2.0 million new cancer cases were diagnosed in the U.S. Furthermore, manufacturers’ continuous investments in R&D are leading to the development of innovative methotrexate drug formulations, uplifting the country’s position in the regional market.

In Canada, the strong presence of research organizations such as the Canadian Cancer Society, the Canadian Breast Cancer Foundation, and the Canadian Institutes of Health Research and the government’s supportive policies for drug discovery are augmenting the methotrexate market growth. For instance, in November 2024, McMaster University revealed that it received around USD 4.0 million from the government for the upgradation and future-proofing of its drug discovery infrastructure.

Asia Pacific Market Statistics

The Asia Pacific methotrexate market is anticipated to expand at the fastest pace during the forecast period. The increasing expansion of international pharma companies, the growing governments’ investments in advancing their medical baskets, and rising investments in R&D for the development of effective autoimmune disorders are set to propel the sales of methotrexate solutions in the coming years. China, India, South Korea, and Japan are high-earning marketplaces for methotrexate producers.

In India, the rising cases of cancer are generating robust strides for the adoption of methotrexate drugs. For instance, according to the National Institutes of Health (NIH), cancer cases are set to rise from 1.4 million in 2022 to 1.5 million by 2025, in India. The government’s support for the expansion of the pharma sector is anticipated to boost the production of methotrexate drugs in the country. The India Brand Equity Foundation (IBEF) reveals that the government under its Strengthening of Pharmaceutical Industry (SPI) scheme invested around USD 60.,9 million to enhance the productivity, quality, and sustainability of the existing pharma clusters and MSMEs in the country.

In China, the rising population of senior citizens who are more susceptible to autoimmune disorders such as cancer and arthritis is fueling the consumption of methotrexate drugs. The government's increasing investments in advancing its healthcare facilities are creating lucrative opportunities for methotrexate market.